1. Male or female subjects ≥18 years and < 80 years. 2. Laboratory-confirmed SARS-CoV-2 infection by PCR for the first time within 72 hours prior to randomization 3. Diagnosis of pneumonia based on: Radiographic infiltrates by imaging (chest x-ray, CT scan) AND 3 of the following clinical symptoms: new onset cough, fever, fatigue, sputum (all day), tachypnea, dyspnea, pleuritic chest pain AND CRP value > 10 mg/L 4. Patients with blood leukocyte count > 4.0 x 109 /L and lymphocyte count > 0.7 x 109 /L 5. Patients with SpO2≤94% on room air or Pa02/FI02 ratio <300mgHg at screening 6. Patients capable to give consent and who have signed the informed consent form before any trial related assessment. 7. Medically accepted effective contraception for women of childbearing potential (WOCBP) which should be continued until at least 90 days after the last dose of trial treatment.

1. Male or female subjects ≥18 years and < 80 years. 2. Laboratory-confirmed SARS-CoV-2 infection by PCR for the first time within 72 hours prior to randomization 3. Diagnosis of pneumonia based on: Radiographic infiltrates by imaging (chest x-ray, CT scan) AND 3 of the following clinical symptoms: new onset cough, fever, fatigue, sputum (all day), tachypnea, dyspnea, pleuritic chest pain AND CRP value > 10 mg/L 4. Patients with blood leukocyte count > 4.0 x 109 /L and lymphocyte count > 0.7 x 109 /L 5. Patients with SpO2≤94% on room air or Pa02/FI02 ratio <300mgHg at screening 6. Patients capable to give consent and who have signed the informed consent form before any trial related assessment. 7. Medically accepted effective contraception for women of childbearing potential (WOCBP) which should be continued until at least 90 days after the last dose of trial treatment.